seed
Stage
1
Investors
About
Biosergen is a biotech company developing novel antifungal drugs, including their lead candidate BSG005, a genetically improved polyene macrolide designed to treat invasive fungal infections in immunocompromised patients. The company originated from technology developed in collaboration with NTNU and SINTEF and has completed a Phase 1 study with ongoing proof-of-concept work.
Explore Biosergen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.